10-Q: NEONC Technologies Q3 2025: NASDAQ Listing Amidst Rising Losses

NEONC Technologies reported significantly increased net losses in Q3 2025 despite a NASDAQ listing and capital raises, facing substantial doubt about its going concern ability.

Summary

• NEONC Technologies Holdings, Inc. (NTHI) reported a net loss of $8,615,920 for the three months ended September 30, 2025, a significant increase from $2,184,500 for the same period in 2024.
• For the nine months ended September 30, 2025, the net loss was $46,622,106, compared to $9,645,482 for the nine months ended September 30, 2024.
• The company's accumulated deficit reached $97,230,551 as of September 30, 2025.
• Cash and cash equivalents stood at $1,513,224 as of September 30, 2025, up from $64,893 at December 31, 2024, primarily due to financing activities.
• Total liabilities increased to $15,897,186 at September 30, 2025, from $8,922,202 at December 31, 2024.
• The company successfully listed on the NASDAQ Global Market on March 26, 2025, and raised $11,644,005 from a private placement.
• An Equity Purchase Agreement with Mast Hill Fund, LP allows for the sale of up to $50,000,000 of common stock, with $3,198,735 net proceeds received during the nine months ended September 30, 2025.
• Convertible promissory notes totaling $4,000,000 were entered into in July 2025, with an effective interest rate of approximately 7.72% per annum.
• Material weaknesses in internal control over financial reporting were identified, including issues with segregation of duties, entity-level controls, financial controls, related party transactions, and IT user access management.
• The company's lead product candidate, NEO100, is in Phase 2a clinical trials for glioblastoma and has Orphan Drug and Fast Track designation from the FDA.
• NEO212 has completed preclinical testing, an IND application has been filed and accepted, and Phase 1 clinical trials have commenced for primary and secondary malignant brain cancer types.
• Two NIH grants totaling approximately $1,407,000 in gross proceeds were awarded in August and September 2025, with the company's net portion estimated at $405,000.
• A Master Services Agreement was signed with IROS, a UAE-based CRO, for a multi-site, randomized Phase 2b/3 study of intranasal NEO100.
• The company acquired a single patented asset from J&B Holdings LLC for $500,000 cash and shares in October 2025.
• Outstanding litigation settlement payables include $4,000,000 to Orient EuroPharma Co., Ltd. and $600,000 plus accrued interest to a vendor, both unpaid and in default.

Sentiment

Score: 2

Explanation: The sentiment is overwhelmingly negative due to the explicit 'going concern' warning, significantly escalating net losses, and identified material weaknesses in internal controls. While there are positive developments in clinical trials, capital raises, and strategic partnerships, these are overshadowed by the severe financial distress and operational control issues, indicating a high level of risk and uncertainty for investors.

Positives

• Successfully listed on the NASDAQ Global Market on March 26, 2025, enhancing market visibility and access to capital.
• Raised significant capital through a private placement ($11,644,005) and an Equity Purchase Agreement with Mast Hill Fund, LP (up to $50,000,000, with $3,198,735 net proceeds received to date).
• Secured $4,000,000 through convertible promissory notes, providing additional liquidity.
• NEO100, the lead product candidate, is in Phase 2a clinical trials for glioblastoma and holds Orphan Drug and Fast Track designations from the FDA, indicating potential for expedited review.
• NEO212 has advanced to Phase 1 clinical trials for primary and secondary malignant brain cancer types, expanding the clinical pipeline.
• Awarded two NIH grants totaling approximately $1,407,000 in gross proceeds, providing non-dilutive funding for research.
• Formed a subsidiary, NuroMENA, and entered into a Letter of Intent for an investment and joint venture with a Middle-East investor, Quazar Investments, potentially bringing $400,000 initial investment and sourcing up to $50,000,000 in future funding.
• Signed a Master Services Agreement with IROS, a UAE-based CRO, to conduct a Phase 2b/3 study for intranasal NEO100, indicating progress in international clinical development.
• Acquired a patented asset from J&B Holdings LLC, strengthening the intellectual property portfolio.

Negatives

• Incurred a substantial net loss of $8,615,920 for the three months and $46,622,106 for the nine months ended September 30, 2025, significantly higher than prior periods.
• Accumulated deficit has grown to $97,230,551, reflecting ongoing operational losses since inception.
• The company does not have sufficient available capital to fund operations for a period of twelve months from the issuance date of these financial statements, raising substantial doubt about its ability to continue as a going concern.
• Total liabilities increased significantly to $15,897,186, driven by accrued advisory fees, litigation settlements, and convertible promissory notes.
• Identified material weaknesses in internal control over financial reporting, including segregation of duties, entity-level controls, financial controls, related party transactions, and IT user access management.
• Outstanding litigation settlement payables totaling $4,746,250 (including accrued interest) remain unpaid, with the company in default on at least one settlement.
• Revenue from humanitarian use cases was minimal ($39,990 for nine months ended September 30, 2025) and not from core product sales.
• Significant increase in general and administrative expenses, primarily due to a marketing campaign, increased employee headcount, rent, travel, and expenses related to the Middle East deal.
• Share-based compensation expense increased substantially to $25,964,096 for the nine months ended September 30, 2025, impacting net loss.

Risks

• Substantial doubt exists regarding the company's ability to continue as a going concern due to insufficient capital to fund operations for the next twelve months.
• The company is dependent on obtaining additional financing, which may not be available when needed, on favorable terms, or at all, potentially forcing delays or termination of research and development programs.
• Risks common to biopharmaceutical companies, including new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, and product liability.
• Reliance on third-party and single-source suppliers for product development and manufacturing.
• Uncertainty of market acceptance and regulatory approvals from the FDA and foreign jurisdictions for product candidates.
• Inability to develop or manufacture future products at an acceptable cost with appropriate performance characteristics or to successfully market them.
• The successful development of product candidates is highly uncertain, with numerous factors impacting costs and timing, including clinical trial outcomes, regulatory approvals, and commercialization capabilities.
• Material weaknesses in internal control over financial reporting could adversely affect the company's ability to record, process, summarize, and report financial information accurately.
• Outstanding litigation settlement payables and potential future legal proceedings could result in material adverse effects on financial position, results of operations, or cash flows.
• Future equity or convertible debt financings could lead to significant dilution for existing shareholders.
• Additional debt financing may involve restrictive covenants limiting the company's operational flexibility.
• If funds are raised through collaborations, valuable rights to technologies or future revenue streams may need to be relinquished.

Future Outlook

The company expects to continue incurring significant and increasing expenses and operating losses as it advances product candidates through preclinical and clinical development, seeks regulatory approval, expands its intellectual property portfolio, and operates as a public company. Substantial additional funding will be required to support continuing operations and growth strategy, likely through public or private equity offerings, debt financings, or collaboration agreements. The ability to raise such funds on acceptable terms is uncertain, and failure to do so could materially adversely affect the business.

Management Comments

• Our operations have focused on organizing and staffing, business planning, raising capital, acquiring and developing technology, establishing intellectual property, identifying product candidates, and undertaking preclinical and clinical studies and manufacturing.
• We do not have any products approved for sale and have not generated any revenue from product sales other than for humanitarian usage.
• We expect to continue to incur significant and increasing expenses and operating losses for the foreseeable future as we advance our current and future product candidates through preclinical and clinical development.
• We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for our product candidates.
• We will need substantial additional funding to support our continuing operations and pursue our growth strategy.
• We expect to finance our operations through a combination of public or private equity offerings and debt financings or other sources, such as potential collaboration agreements, strategic alliances and licensing arrangements.
• Our failure to raise capital or enter into such agreements as, and when needed, could have a material adverse effect on our business, results of operations and financial condition.
• Management believes that the consolidated financial statements included in this Form 10-Q present fairly in all material respects our financial position, results of operations, and cash flows for the period presented, despite internal control weaknesses.

Industry Context

NEONC Technologies operates in the highly competitive and capital-intensive biopharmaceutical industry, specializing in treatments for central nervous system diseases, particularly aggressive brain cancers like glioblastoma. The company faces common industry challenges such as lengthy and uncertain drug development cycles, high R&D costs, stringent regulatory approval processes (FDA, foreign jurisdictions), and the need for substantial ongoing financing. Its focus on novel drug delivery methods, like intranasal delivery for NEO100 to bypass the blood-brain barrier, positions it in a niche with high unmet medical need but also significant scientific and commercial hurdles. The recent NASDAQ listing and pursuit of international partnerships (e.g., NuroMENA, IROS) reflect a strategy to broaden funding sources and market reach, typical for clinical-stage biotech firms seeking to de-risk and accelerate development.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• A litigation settlement payable of $4,000,000 to Orient EuroPharma Co., Ltd. (OEP) remains unpaid as of September 30, 2025. This settlement was agreed upon in February 2024 for the termination of a collaboration agreement and was due within ten days of the company's initial public offering (March 26, 2025).
• A litigation settlement payable of $600,000 plus accrued interest to a vendor (Fox Infused, LLC) remains unpaid as of September 30, 2025. This settlement, for breach of contract, was due by March 31, 2024, then extended to May 15, 2024, and the company is currently in default. Accrued interest of $146,250 was recognized for the nine months ended September 30, 2025.

Related Party Transactions

• AFH Holdings and Advisory, LLC, an affiliate, was retained for advisory services related to the public listing. A fee of $11,328,565 was incurred on March 26, 2025, with $2,500,000 paid and a remaining balance of $3,675,569 accrued as of September 30, 2025, payable in monthly installments.
• The company maintains a license agreement with the University of Southern California (USC), paying an annual patent maintenance fee of $20,000 and 4% nonrefundable earned royalties on Net Sales (none to date). Outstanding payables to USC for services totaled $499,607 as of September 30, 2025.
• HCWG LLC previously provided a Bridge Loan, which was converted into 979,039 shares of common stock and terminated in June 2024. The company has a receivable of $138,247 due from HCWG LLC.
• A Line of Credit Agreement with HCWG for up to $10.0 million was entered into on October 11, 2024. No amounts have been borrowed through September 30, 2025. Warrants to purchase 312,500 shares were issued to HCWG, with 150,000 shares remaining available under the warrant as of September 30, 2025.
• The Executive Chairman advanced approximately $300,000 to the company in February 2025, which was repaid with 1x interest ($300,000) in March 2025.
• Convertible promissory notes totaling $4,000,000 were entered into with a group of investors in July 2025. Interest expense related to these notes is categorized under 'interest expense related parties' in the segment reporting.

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing and future equity capital raises, as well as potential loss of investment due to the 'going concern' uncertainty and mounting accumulated deficit.
• Employees may face job insecurity given the company's liquidity challenges and the 'going concern' warning, despite increased headcount in some areas.
• Customers/Patients could benefit from the continued development of NEO100 and NEO212 for severe brain cancers, but the company's financial instability poses a risk to the long-term viability of these programs.
• Suppliers and creditors, particularly those with unpaid litigation settlements, face uncertainty regarding payment collection due to the company's liquidity issues and default status on certain obligations.
• Regulatory bodies (e.g., SEC, NASDAQ) are impacted by the company's identified material weaknesses in internal controls, requiring management to implement remediation steps to ensure compliance and accurate financial reporting.

Next Steps

• Continue advancing NEO100 through Phase 2a clinical trials for recurrent malignant glioma.
• Proceed with Phase 1 clinical trials for NEO212 for primary and secondary malignant brain cancer types.
• Initiate the multi-site, randomized Phase 2b/3 study for intranasal NEO100 through the Master Services Agreement with IROS.
• Secure additional financing through equity offerings, debt financings, or collaboration agreements to address liquidity needs and the going concern issue.
• Remediate identified material weaknesses in internal control over financial reporting, including improving review processes for complex securities and related accounting standards, enhancing access to accounting literature, and considering additional qualified staff.
• Resolve outstanding litigation settlement payables to Orient EuroPharma Co., Ltd. and the vendor (Fox Infused, LLC).
• Finalize the investment and joint venture agreement with Quazar Investments for NuroMena Holdings Ltd. and secure the initial investment.

Key Dates

Recommendation

The company faces severe financial distress, explicitly stating 'substantial doubt' about its ability to continue as a going concern. Net losses have dramatically increased, and the accumulated deficit is nearing $100 million. While there are positive developments in clinical trials and capital raises, these are insufficient to offset the fundamental liquidity crisis and the significant operational risks, including material weaknesses in internal controls and unpaid litigation settlements. The high burn rate and continuous need for dilutive financing, coupled with the going concern warning, make this a highly speculative and risky investment. A seasoned investor would likely recommend a strong sell given the overwhelming financial and operational challenges.

Keywords

Biotechnology, Glioblastoma, Brain Cancer, Clinical Trials, NASDAQ Listing, SEC Filing, 10-Q, NEO100, NEO212, Biopharmaceutical, Orphan Drug, Fast Track, Going Concern, Capital Raise, Internal Controls, Drug Development